KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Current Taxes (2016 - 2019)

Historic Current Taxes for Biomarin Pharmaceutical (BMRN) over the last 10 years, with Q1 2019 value amounting to $11.4 million.

  • Biomarin Pharmaceutical's Current Taxes rose 1105.57% to $11.4 million in Q1 2019 from the same period last year, while for Mar 2019 it was $11.4 million, marking a year-over-year increase of 1105.57%. This contributed to the annual value of $7.8 million for FY2018, which is 2007.19% down from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported Current Taxes of $11.4 million as of Q1 2019, which was up 1105.57% from $7.8 million recorded in Q4 2018.
  • In the past 5 years, Biomarin Pharmaceutical's Current Taxes ranged from a high of $59.6 million in Q4 2015 and a low of $5.7 million during Q1 2015
  • Its 5-year average for Current Taxes is $11.6 million, with a median of $8.6 million in 2018.
  • Its Current Taxes has fluctuated over the past 5 years, first soared by 98727.87% in 2015, then tumbled by 8682.6% in 2016.
  • Over the past 5 years, Biomarin Pharmaceutical's Current Taxes (Quarter) stood at $59.6 million in 2015, then plummeted by 86.83% to $7.8 million in 2016, then increased by 24.11% to $9.7 million in 2017, then decreased by 20.07% to $7.8 million in 2018, then skyrocketed by 45.81% to $11.4 million in 2019.
  • Its last three reported values are $11.4 million in Q1 2019, $7.8 million for Q4 2018, and $8.6 million during Q3 2018.